Press release from Companies: CHOSA Oncology AB’s återbetalning av konvertibellånet pågår

Press release from Companies: CHOSA Oncology AB’s poster Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer antagen till ASCO’s årliga möte

Press release from Companies: CHOSA Oncology AB's abstract Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer accepted at 2023 ASCO Annual Meeting

Press release from Companies: CHOSA Oncology AB initiates payment of last portion of loan given to RhoVac AB

Press release from Companies: CHOSA Oncology AB initierar betalning av sista delen av lånet till RhoVac AB

More from the company: CHOSA Oncology AB presents at Stora Aktiedagarna in Stockholm

More from the company: CHOSA Oncology AB presenterar på Stora Aktiedagarna i Stockholm

Reports: CHOSA Onocology (före detta RhoVac AB) offentliggör bokslutskommuniké för verksamhetsåret 2022

More from the company: CHOSA team to participate at ASCO and present phase II data from the iCIP study

More from the company: CHOSA-teamet kommer delta på ASCO och presentera fas II-data från iCIP-studien

Market Notices: Market Notice 36/23 – RhoVac AB changes name to CHOSA Oncology AB

Market Notices: Market Notice 36/23 – RhoVac AB changes name to CHOSA Oncology AB